Progenics Highlights Presentation Of Updated Survival Data For AZEDRA In Advanced Pheochromocytoma And Paraganglioma; Patients Treated With AZEDRA Show Overall Survival Of 73.1% At Two Years And 44.2% At Four Years
Benzinga Newsdesk